- Cash & cash equivalents and liquid investments of ¤32.8 million as of December 31st, 2014
- ProCervix phase 2 study enrollment completed ahead of schedule
- Genticel wins the Deloitte Technology Fast 50 "Biotech d'Avenir" for 2014
- Post quarter close news: ProCervix phase 2 clinical study to continue as planned after 2nd review by DSMB
GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces its cash & cash equivalents and liquid investments position and its highlights from the fourth quarter of 2014.
Financial highlights - Fourth quarter 2014
As of December 31st, 2014, Genticel's net cash & cash equivalents and liquid investments position was ¤32.8 million (vs. ¤35.3 million on September 30th, 2014), fully in line with the company's expectations for these items.
Given the current development stage of its therapeutic vaccines candidates and the company's value-creation strategy for these assets, Genticel has as of yet no revenue to report.
Business highlights - Fourth quarter 2014
239 patients enrolled ahead of schedule in the ProCervix phase 2 study
With the last patient enrolled on November 10th, 2014, Genticel completed the enrollment at least four months in advance, reaching yet another significant milestone in the ProCervix development program.
Genticel wins the 2014 Deloitte Technology Fast 50 "Biotech d'Avenir" (Most Promising Biotech) award for SW France
The Deloitte Technology Fast 50 program recognizes fast-growing innovative technology companies. For its Life Sciences awards, growth is measured by the amount of capital raised during the financial year 2013. This trophy is a recognition of Genticel's strategy that includes giving the company the financial means necessary for the clinical development of its innovative candidate drugs.
Post quarter close news: ProCervix phase 2 trial to continue as planned after 2nd DSMB review on January 22nd, 2015
The Data and Safety Monitoring Board (DSMB), an independent committee of experts that monitors safety data every six months during the study, completed its second safety assessment of the phase 2 clinical study with ProCervix and unanimously recommended the continuation of the trial without any modification. The DSMB had previously made the same recommendation during its first review on July 1st, 2014.
Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.
Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.
Genticel is based in Paris and Toulouse and was awarded 2014 "Prix Biotech d'Avenir" (Most Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark.
Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.
For more information, please visit Genticel's website www.genticel.com
|USA INVESTOR CONTACT||INVESTOR CONTACT||PRESS CONTACT|
Chief Executive Officer
Tel.: +1 (212) 915 2577
Tel.: +33 (0)1 53 67 36 77
Tel.: +33 (0)1 53 67 36 90
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Communiqué intégral et original au format PDF :
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|GENKYOTEX||Euronext Paris||1.88 (c)||0.53%||2 689|